I Marinou1, K Walters, J Winfield, D E Bax, A G Wilson. 1. Section of Musculoskeletal Sciences, School of Medicine and Biomedical Sciences, The University of Sheffield, Royal Hallamshire Hospital, Sheffield S10 2JF, UK.
Abstract
OBJECTIVES: To investigate the possible role of a functional polymorphism in the soluble interleukin 6 receptor (sIL-6R) gene in the genetic background of rheumatoid arthritis (RA). METHODS: An association between disease status and the sIL-6R rs8192284 (A358D) variant was tested in 965 patients with RA and 988 unrelated healthy controls. Odds ratios (ORs) for disease were calculated with asymptotic 95% CI; p values <0.05 were considered statistically significant after adjustment for multiple testing. To determine the relationship between protein levels and IL-6R A358D genotype, the protein levels of sIL-6R in 100 plasma samples from healthy controls were measured using an ELISA and compared across the genotype groups. RESULTS: The allele frequency of the C allele (alanine) was lower in cases than in controls (38.4% vs 41.7%, p=0.04, OR 0.9, 95% CI 0.8 to 1.0), as were the CC/AC genotypes compared with AA genotype frequencies (61.0% in RA cases vs 67.5% in controls, p=0.004, OR 0.8, 95% CI 0.6 to 0.9). Plasma levels of sIL-6R differed significantly according to genotype in the controls: 17.00 + or - 2.03 ng/ml for A/A, 20.08 + or - 1.83 ng/ml for A/C and 21.57 + or - 2.10 ng/ml for C/C (p=0.0001). CONCLUSION: These data suggest a role for genetically determined lower sIL-6R levels as a risk factor for RA. The proinflammatory role of the IL6 system in established RA has been highlighted by the use of anti-sIL-6R antibodies. However, the findings of this study suggest a protective effect of IL6 on the risk of developing RA.
OBJECTIVES: To investigate the possible role of a functional polymorphism in the soluble interleukin 6 receptor (sIL-6R) gene in the genetic background of rheumatoid arthritis (RA). METHODS: An association between disease status and the sIL-6R rs8192284 (A358D) variant was tested in 965 patients with RA and 988 unrelated healthy controls. Odds ratios (ORs) for disease were calculated with asymptotic 95% CI; p values <0.05 were considered statistically significant after adjustment for multiple testing. To determine the relationship between protein levels and IL-6RA358D genotype, the protein levels of sIL-6R in 100 plasma samples from healthy controls were measured using an ELISA and compared across the genotype groups. RESULTS: The allele frequency of the C allele (alanine) was lower in cases than in controls (38.4% vs 41.7%, p=0.04, OR 0.9, 95% CI 0.8 to 1.0), as were the CC/AC genotypes compared with AA genotype frequencies (61.0% in RA cases vs 67.5% in controls, p=0.004, OR 0.8, 95% CI 0.6 to 0.9). Plasma levels of sIL-6R differed significantly according to genotype in the controls: 17.00 + or - 2.03 ng/ml for A/A, 20.08 + or - 1.83 ng/ml for A/C and 21.57 + or - 2.10 ng/ml for C/C (p=0.0001). CONCLUSION: These data suggest a role for genetically determined lower sIL-6R levels as a risk factor for RA. The proinflammatory role of the IL6 system in established RA has been highlighted by the use of anti-sIL-6R antibodies. However, the findings of this study suggest a protective effect of IL6 on the risk of developing RA.
Authors: Patrick C G Haddick; Jessica L Larson; Nisha Rathore; Tushar R Bhangale; Qui T Phung; Karpagam Srinivasan; David V Hansen; Jennie R Lill; Margaret A Pericak-Vance; Jonathan Haines; Lindsay A Farrer; John S Kauwe; Gerard D Schellenberg; Carlos Cruchaga; Alison M Goate; Timothy W Behrens; Ryan J Watts; Robert R Graham; Joshua S Kaminker; Marcel van der Brug Journal: J Alzheimers Dis Date: 2017 Impact factor: 4.472
Authors: Julie E Gibbs; John Blaikley; Stephen Beesley; Laura Matthews; Karen D Simpson; Susan H Boyce; Stuart N Farrow; Kathryn J Else; Dave Singh; David W Ray; Andrew S I Loudon Journal: Proc Natl Acad Sci U S A Date: 2011-12-19 Impact factor: 11.205
Authors: Luis Rodríguez-Rodríguez; José Ramón Lamas; Jezabel Varadé; Pedro López-Romero; Pilar Tornero-Esteban; Lydia Abasolo; Emilio Gomez de la Concha; Juan Angel Jover; Elena Urcelay; Benjamín Fernández-Gutiérrez Journal: Rheumatol Int Date: 2010-07-27 Impact factor: 2.631
Authors: Nadeem Sarwar; Adam S Butterworth; Daniel F Freitag; John Gregson; Peter Willeit; Donal N Gorman; Pei Gao; Danish Saleheen; Augusto Rendon; Christopher P Nelson; Peter S Braund; Alistair S Hall; Daniel I Chasman; Anne Tybjærg-Hansen; John C Chambers; Emelia J Benjamin; Paul W Franks; Robert Clarke; Arthur A M Wilde; Mieke D Trip; Maristella Steri; Jacqueline C M Witteman; Lu Qi; C Ellen van der Schoot; Ulf de Faire; Jeanette Erdmann; Heather M Stringham; Wolfgang Koenig; Daniel J Rader; David Melzer; David Reich; Bruce M Psaty; Marcus E Kleber; Demosthenes B Panagiotakos; Johann Willeit; Patrik Wennberg; Mark Woodward; Svetlana Adamovic; Eric B Rimm; Tom W Meade; Richard F Gillum; Jonathan A Shaffer; Albert Hofman; Altan Onat; Johan Sundström; Sylvia Wassertheil-Smoller; Dan Mellström; John Gallacher; Mary Cushman; Russell P Tracy; Jussi Kauhanen; Magnus Karlsson; Jukka T Salonen; Lars Wilhelmsen; Philippe Amouyel; Bernard Cantin; Lyle G Best; Yoav Ben-Shlomo; JoAnn E Manson; George Davey-Smith; Paul I W de Bakker; Christopher J O'Donnell; James F Wilson; Anthony G Wilson; Themistocles L Assimes; John-Olov Jansson; Claes Ohlsson; Åsa Tivesten; Östen Ljunggren; Muredach P Reilly; Anders Hamsten; Erik Ingelsson; Francois Cambien; Joseph Hung; G Neil Thomas; Michael Boehnke; Heribert Schunkert; Folkert W Asselbergs; John J P Kastelein; Vilmundur Gudnason; Veikko Salomaa; Tamara B Harris; Jaspal S Kooner; Kristine H Allin; Børge G Nordestgaard; Jemma C Hopewell; Alison H Goodall; Paul M Ridker; Hilma Hólm; Hugh Watkins; Willem H Ouwehand; Nilesh J Samani; Stephen Kaptoge; Emanuele Di Angelantonio; Olivier Harari; John Danesh Journal: Lancet Date: 2012-03-14 Impact factor: 79.321
Authors: Renata Sokolik; Milena Iwaszko; Jerzy Świerkot; Barbara Wysoczańska; Lucyna Korman; Piotr Wiland; Katarzyna Bogunia-Kubik Journal: Pharmgenomics Pers Med Date: 2021-01-28